Composition for assisting in maintaining blood fat health and preparation method thereof
By preparing a combination of hawthorn, lotus leaf, Pu-erh tea, salvia miltiorrhiza and kudzu root, the problems of high adverse reactions and low medication compliance in patients with dyslipidemia who take medication for a long time are solved. This provides a low-dose and effective lipid health adjuvant composition that significantly reduces the blood lipid level in hyperlipidemic rats.
Patent Information
- Application Number
- CN202511403088.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-09-29
- Publication Date
- 2025-12-23
AI Technical Summary
In the existing technology, patients with dyslipidemia need to take medication for a long time to control their blood lipid levels, which has problems such as high adverse reactions and low medication compliance. In addition, the daily dosage of the existing compositions is relatively large.
A composition using hawthorn, lotus leaf, Pu-erh tea, salvia miltiorrhiza and kudzu root as the main ingredients was prepared by heating and reflux extraction, vacuum concentration and centrifugation to produce a composition that helps maintain healthy blood lipids, with a low average daily dosage.
This composition significantly reduces the levels of total cholesterol, triglycerides, and low-density lipoprotein cholesterol in hyperlipidemic rats by working together to eliminate stagnation, strengthen the spleen and remove turbidity, promote blood circulation and remove blood stasis, soothe the liver and regulate qi, and benefit the kidneys and eliminate turbidity. It also improves medication compliance and reduces the occurrence of adverse reactions.
Smart Images

Figure BDA0005619439640000081 
Figure BDA0005619439640000082 
Figure BDA0005619439640000091
Abstract
Description
Technical Field
[0001] This invention belongs to the field of blood lipid health technology, and relates to a composition that helps maintain healthy blood lipids and its preparation method. Background Technology
[0002] With rapid economic development and profound changes in lifestyle, dyslipidemia is becoming increasingly prominent in the Chinese population. A 2018 survey showed that 35.6% of people in China had dyslipidemia, and this figure is projected to rise further to 40.4% by 2024. Dyslipidemia is a common metabolic syndrome characterized by elevated levels of total cholesterol, triglycerides, and low-density lipoprotein cholesterol, and decreased levels of high-density lipoprotein cholesterol. Dyslipidemia is a major risk factor for cardiovascular disease. Therefore, maintaining healthy blood lipid levels is crucial for individual health.
[0003] Patients with dyslipidemia typically require long-term medication to control their lipid levels. This is because lipid metabolism disorders are often related to irreversible factors such as genetics, age, and metabolic dysfunction, and are classified as chronic, progressive diseases. Clinical studies have confirmed that after discontinuing lipid-lowering drugs, the lipid levels of most patients gradually return to their pre-treatment levels. Long-term use of high doses of lipid-lowering drugs may increase the incidence of adverse reactions. For example, common adverse reactions to statins include gastrointestinal discomfort and myalgia; in severe cases, myopathy or abnormal liver function may occur. Furthermore, some studies have found that higher doses may increase the burden of medication for patients, thereby reducing medication adherence.
[0004] Therefore, developing a composition that helps maintain healthy blood lipids with a low daily dosage has become a problem that urgently needs to be solved by those skilled in the art. Summary of the Invention
[0005] To address the problems existing in the prior art, the present invention provides a composition for assisting in maintaining healthy blood lipids and a method for preparing the same. The technical solution adopted by the present invention is as follows:
[0006] The first aspect of the present invention provides a composition for assisting in maintaining healthy blood lipids, the composition comprising the following ingredients in the following weight proportions: 80-120 parts hawthorn; 55-95 parts lotus leaf; 55-95 parts Pu-erh tea; 40-80 parts salvia miltiorrhiza; 40-80 parts kudzu root; and 20-40 parts Panax notoginseng.
[0007] In a preferred embodiment of the present invention, the composition comprises the following ingredients in the following weight proportions: 90-110 parts hawthorn, 70-90 parts lotus leaf, 70-90 parts Pu-erh tea, 50-70 parts salvia miltiorrhiza, 50-70 parts kudzu root, and 30-40 parts Panax notoginseng.
[0008] In a preferred embodiment of the present invention, the composition comprises the following ingredients in the following weight proportions: 100-105 parts hawthorn, 80-85 parts lotus leaf, 80-85 parts Pu-erh tea, 60-70 parts salvia miltiorrhiza, 60-70 parts kudzu root, and 35-40 parts Panax notoginseng.
[0009] In a preferred embodiment of the present invention, the weight ratio of the lotus leaf and the Pu-erh tea is 1:0.8 to 1.2, preferably 1:0.9 to 1.1.
[0010] In a preferred embodiment of the present invention, the sum of the weight parts of the lotus leaf and the Pu-erh tea is greater than the sum of the weight parts of the dan ginseng and the kudzu root.
[0011] In a preferred embodiment of the present invention, the ratio of the sum of the weight parts of the lotus leaf and the Pu-erh tea to the sum of the weight parts of the salvia miltiorrhiza and the kudzu root is 1.2 to 1.3:1.
[0012] A second aspect of the present invention provides a method for preparing a composition that helps maintain healthy blood lipids, comprising the following steps,
[0013] S1: Weigh out hawthorn, lotus leaf, Pu-erh tea, salvia miltiorrhiza, kudzu root, and notoginseng according to the weight proportions of each raw material in the composition provided in the first aspect of the present invention;
[0014] S2: Add 10 to 14 times the amount of water to hawthorn, lotus leaf, Pu-erh tea, salvia miltiorrhiza, kudzu root, and notoginseng, heat under reflux to obtain the extract;
[0015] S3: The extract is concentrated under reduced pressure to a relative density of 1.05-1.15, and then filtered through a 300-mesh filter cloth to obtain a concentrated extract;
[0016] S4: After centrifugation of the concentrated extract, the centrifuged liquid is obtained. After drying the centrifuged liquid, it is passed through a 40-mesh sieve to obtain a composition that helps maintain healthy blood lipids.
[0017] In a preferred embodiment of the present invention
[0018] In step S2, the extraction is performed by heating and reflux 2–4 times, with each reflux lasting 1–2 hours; and / or,
[0019] In step S3, the temperature for vacuum concentration is 40–80°C, and the vacuum degree for vacuum concentration is -0.04–-0.09 MPa; and / or,
[0020] In step S4, the centrifugation speed is 10000-16000 rpm and the centrifugation time is 2-5 min.
[0021] Compared with the prior art, the beneficial effects of the present invention are as follows:
[0022] The composition of this invention exhibits synergistic effects, working together to eliminate stagnation, strengthen the spleen and resolve turbidity, promote blood circulation and remove blood stasis, soothe the liver and regulate qi, and benefit the kidneys and eliminate turbidity, ultimately achieving the effect of assisting in maintaining healthy blood lipids. Furthermore, the daily dosage of the composition of this invention is low, and its long-term safety is high, which can reduce the occurrence of adverse reactions to a certain extent and improve patient medication adherence. This has significant economic implications for patients with dyslipidemia who require long-term medication. Detailed Implementation
[0023] The present invention will now be described in detail with reference to specific embodiments. It should be noted that the following embodiments are only used to further illustrate the present invention and should not be construed as limiting the scope of protection of the present invention. Some non-essential improvements and adjustments made by those skilled in the art based on the content of the present invention are still within the scope of protection of the present invention.
[0024] All raw materials used in the examples are commercially available.
[0025] All instruments used in the examples are commercially available instruments.
[0026] Example 1
[0027] Step 1: Weigh out 85 parts by weight of hawthorn, 95 parts by weight of lotus leaf, 85 parts by weight of Pu-erh tea, 65 parts by weight of salvia miltiorrhiza, 60 parts by weight of kudzu root, and 40 parts by weight of Panax notoginseng.
[0028] Step 2: Add 5160 parts by weight of water to hawthorn, lotus leaf, Pu-erh tea, salvia miltiorrhiza, kudzu root, and Panax notoginseng, and heat under reflux twice, each time for 1.5 hours, to obtain the extract.
[0029] Step 3: The extract is concentrated under reduced pressure at a temperature of 60℃ and a vacuum degree of -0.06MPa. The concentration is continued until the relative density reaches 1.1, then filtered through a 300-mesh filter cloth to obtain a concentrated extract.
[0030] Step 4: Centrifuge the concentrated extract at 10,000 rpm. After drying, pass the centrifuged liquid through a 40-mesh sieve to obtain a powdered composition.
[0031] Example 2
[0032] Step 1: Weigh out 95 parts by weight of hawthorn, 85 parts by weight of lotus leaf, 85 parts by weight of Pu-erh tea, 60 parts by weight of salvia miltiorrhiza, 65 parts by weight of kudzu root, and 40 parts by weight of Panax notoginseng.
[0033] Step 2: Add 5160 parts by weight of water to hawthorn, lotus leaf, Pu-erh tea, salvia miltiorrhiza, kudzu root, and Panax notoginseng, and heat under reflux twice, each time for 1.5 hours, to obtain the extract.
[0034] Step 3: The extract is concentrated under reduced pressure at a temperature of 60℃ and a vacuum degree of -0.06MPa. The concentration is continued until the relative density reaches 1.1, then filtered through a 300-mesh filter cloth to obtain a concentrated extract.
[0035] Step 4: Centrifuge the concentrated extract at 10,000 rpm. After drying, pass the centrifuged liquid through a 40-mesh sieve to obtain a powdered composition.
[0036] Example 3
[0037] Step 1: Weigh out 120 parts by weight of hawthorn, 60 parts by weight of lotus leaf, 85 parts by weight of Pu-erh tea, 65 parts by weight of salvia miltiorrhiza, 65 parts by weight of kudzu root, and 35 parts by weight of Panax notoginseng.
[0038] Step 2: Add 5160 parts by weight of water to hawthorn, lotus leaf, Pu-erh tea, salvia miltiorrhiza, kudzu root, and Panax notoginseng, and heat under reflux twice, each time for 1.5 hours, to obtain the extract.
[0039] Step 3: The extract is concentrated under reduced pressure at a temperature of 60℃ and a vacuum degree of -0.06MPa. The concentration is continued until the relative density reaches 1.1, then filtered through a 300-mesh filter cloth to obtain a concentrated extract.
[0040] Step 4: Centrifuge the concentrated extract at 10,000 rpm. After drying, pass the centrifuged liquid through a 40-mesh sieve to obtain a powdered composition.
[0041] Example 4
[0042] Step 1: Weigh out 105 parts by weight of hawthorn, 80 parts by weight of lotus leaf, 80 parts by weight of Pu-erh tea, 65 parts by weight of salvia miltiorrhiza, 65 parts by weight of kudzu root, and 35 parts by weight of Panax notoginseng.
[0043] Step 2: Add 5160 parts by weight of water to hawthorn, lotus leaf, Pu-erh tea, salvia miltiorrhiza, kudzu root, and Panax notoginseng, and heat under reflux twice, each time for 1.5 hours, to obtain the extract.
[0044] Step 3: The extract is concentrated under reduced pressure at a temperature of 60℃ and a vacuum degree of -0.06MPa. The concentration is continued until the relative density reaches 1.1, then filtered through a 300-mesh filter cloth to obtain a concentrated extract.
[0045] Step 4: Centrifuge the concentrated extract at 10,000 rpm. After drying, pass the centrifuged liquid through a 40-mesh sieve to obtain a powdered composition.
[0046] Comparative Example 1
[0047] Step 1: Weigh out 105 parts by weight of hawthorn, 80 parts by weight of Pu-erh tea, 65 parts by weight of salvia miltiorrhiza, 65 parts by weight of kudzu root, and 35 parts by weight of Panax notoginseng.
[0048] Step 2: Add 5160 parts by weight of water to hawthorn, Pu-erh tea, salvia miltiorrhiza, kudzu root, and notoginseng, and heat under reflux twice, each time for 1.5 hours, to obtain the extract.
[0049] Step 3: The extract is concentrated under reduced pressure at a temperature of 60℃ and a vacuum degree of -0.06MPa. The concentration is continued until the relative density reaches 1.1, then filtered through a 300-mesh filter cloth to obtain a concentrated extract.
[0050] Step 4: Centrifuge the concentrated extract at 10,000 rpm. After drying, pass the centrifuged liquid through a 40-mesh sieve to obtain a powdered composition.
[0051] Comparative Example 2
[0052] Step 1: Weigh out 80 parts by weight of lotus leaf, 80 parts by weight of Pu-erh tea, 65 parts by weight of Salvia miltiorrhiza, 65 parts by weight of kudzu root, and 35 parts by weight of Panax notoginseng.
[0053] Step 2: Add 5160 parts by weight of water to lotus leaves, Pu-erh tea, salvia miltiorrhiza, kudzu root, and Panax notoginseng, and heat under reflux twice, each time for 1.5 hours, to obtain the extract.
[0054] Step 3: The extract is concentrated under reduced pressure at a temperature of 60℃ and a vacuum degree of -0.06MPa. The concentration is continued until the relative density reaches 1.1, then filtered through a 300-mesh filter cloth to obtain a concentrated extract.
[0055] Step 4: Centrifuge the concentrated extract at 10,000 rpm. After drying, pass the centrifuged liquid through a 40-mesh sieve to obtain a powdered composition.
[0056] Comparative Example 3
[0057] Step 1: Weigh out 105 parts by weight of hawthorn, 80 parts by weight of lotus leaf, 65 parts by weight of salvia miltiorrhiza, 65 parts by weight of kudzu root, and 35 parts by weight of notoginseng.
[0058] Step 2: Add 5160 parts by weight of water to hawthorn, lotus leaf, salvia miltiorrhiza, kudzu root, and notoginseng, and heat under reflux twice, each time for 1.5 hours, to obtain the extract.
[0059] Step 3: The extract is concentrated under reduced pressure at a temperature of 60℃ and a vacuum degree of -0.06MPa. The concentration is continued until the relative density reaches 1.1, then filtered through a 300-mesh filter cloth to obtain a concentrated extract.
[0060] Step 4: Centrifuge the concentrated extract at 10,000 rpm. After drying, pass the centrifuged liquid through a 40-mesh sieve to obtain a powdered composition.
[0061] Comparative Example 4
[0062] The composition of this comparative example was prepared according to Formulation 1 of CN101524421A and the first process of Formulation 1. The first process includes the following steps:
[0063] Step 1: Weigh out 100 parts by weight of Salvia miltiorrhiza, 100 parts by weight of Pueraria lobata, 100 parts by weight of hawthorn, 80 parts by weight of lotus leaf, 80 parts by weight of Ligusticum chuanxiong, 60 parts by weight of ginkgo leaf, and 12 parts by weight of Panax notoginseng.
[0064] Step 2: Add water to the danshen, kudzu root, hawthorn, lotus leaf, chuanxiong, ginkgo leaf, and sanqi and decoct twice, 2 hours each time. Combine the decoctions, filter, and concentrate the filtrate under reduced pressure to a thick paste of 1.25. Dry and pulverize into a fine powder.
[0065] Experimental Example 1: Animal Functional Experiment
[0066] 1. Preparation of test samples
[0067] 1.1 Test Samples in Example Group
[0068] Test samples of Examples 1 to 4: The compositions prepared in Examples 1 to 4 were weighed and dissolved in sterile water to obtain test samples of Examples 1, 2, 3 and 4 respectively. The concentration of each of the four test samples was 200 mg / mL.
[0069] 1.2 Comparative control group test samples
[0070] Comparative Examples 1 to 3: The compositions prepared in Comparative Examples 1 to 3 were weighed and dissolved in sterile water to obtain Comparative Example 1, Comparative Example 2, and Comparative Example 3 test samples, respectively. The concentration of each of the three test samples was 200 mg / mL.
[0071] Comparative Example 4 test samples: Weigh the composition prepared in Comparative Example 4, dissolve it in sterile water to obtain Comparative Example 4 test samples, the concentration of which is 690 mg / mL.
[0072] 2. Animal grouping, drug administration, and testing
[0073] 2.1 Test animals and animal grouping
[0074] SPF-grade male SD rats, weighing 150±10g, were used as test animals and provided by Beijing Huafukang Biotechnology Co., Ltd. The specific housing environment for the test animals was as follows: room temperature maintained at approximately 24±2℃, relative humidity at 50±10%, and a pathogen-free standard environment. The SPF-grade male SD rats were acclimatized for one week before model establishment and drug administration.
[0075] Table 1. Test animals and animal groups
[0076] Group test animals weight Number of animals Blank group SPF-grade male SD rats 150±10g 12 Modeling group SPF-grade male SD rats 150±10g 108
[0077] 2.2 Animal Modeling
[0078] Table 2. Animal Modeling in Tests
[0079] Group Days 1-14 Blank group ordinary feed Modeling group High-fat feed
[0080] During days 1-14, the control group was given a normal diet, while the model group was given a high-fat diet (normal diet supplemented with 20% sucrose, 15% lard, 1.2% cholesterol, and 0.2% sodium cholate) and free access to water. Both the normal and high-fat diets were provided by Beijing Huafukang Biotechnology Co., Ltd.
[0081] 2.3 Animal testing in the blank control group and the model group
[0082] Both the control group and the model group were fed a diet for 14 days without fasting, and blood was collected. Serum was then separated, and the levels of total cholesterol (TC), triglycerides (TG), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) were measured. Based on TC levels, the model group was randomly divided into 9 groups: the model group, Example 1 to Example 4 groups, and Comparative Example 1 to Comparative Example 4 groups. It should be noted that after randomization into 9 groups, there were no significant differences in TC, TG, LDL-C, and HDL-C levels between the model group and the other 8 groups. Furthermore, after randomization into 9 groups, the increases in TC, TG, or LDL-C in any of the 9 groups compared to the control group were statistically significant.
[0083] 2.4 Dosing in test animals
[0084] The recommended dose of this product is 8g / 60kg body weight (bw) per day for humans. Examples and Comparative Examples 1-3 were administered at 15 times the recommended human dose, i.e., 200mg crude drug / 100g bw per day. Comparative Example 4 was administered at its low-dose group of 690mg crude drug / 100g bw. The test samples from the aforementioned examples and comparative examples were administered directly by gavage.
[0085] Table 3. Dosing in test animals (days 15–46)
[0086] Group feed Test sample Test sample dose Blank group ordinary feed sterile water 1mL / 100g·bw Model group High-fat feed sterile water 1mL / 100g·bw Example 1 Group High-fat feed Example 1: Group of test samples 200mg crude drug / 100g·bw Example 2 group High-fat feed Example 2: Group of test samples 200mg crude drug / 100g·bw Example 3 Group High-fat feed Example 3: Group of test samples 200mg crude drug / 100g·bw Example 4 group High-fat feed Example 4: Group of test samples 200mg crude drug / 100g·bw Comparative Example 1 High-fat feed Comparative Example 1: Test Samples 200mg crude drug / 100g·bw Comparative Example 2 High-fat feed Comparative Example 2 test samples 200mg crude drug / 100g·bw Comparative Example 3 Groups High-fat feed Comparative Example 3 test samples 200mg crude drug / 100g·bw Comparative Example 4 Groups High-fat feed Comparative Example 4 test samples 690mg crude drug / 100g·bw
[0087] 2.5 Testing of test animals and statistical analysis of data
[0088] After 31 days of continuous gavage administration, blood samples were collected from the test animals without fasting to measure the serum levels of TC, TG, and LDL-C. Data processing was performed using statistical software. First, a homogeneity of variance test was conducted. If the variances were homogeneous, one-way ANOVA was used for overall comparison. If differences were found, Dunnett's method was used for pairwise comparisons between the means of multiple dose groups and a control group. Independent samples t-tests were used to compare the experimental data of the model group and the control group before and after administration of the test substance.
[0089] 3 Results and Discussion
[0090] 3.1 Effect of the composition on serum total cholesterol (TC) in hyperlipidemic rats.
[0091] Table 4. Effects of the composition on serum TC in hyperlipidemic rats
[0092]
[0093] In the table, ## indicates a highly significant difference between the model group and the control group (P<0.01); ### indicates a highly significant difference between the model group and the control group (P<0.001); * indicates a significant difference between the group and the model group (P<0.05); ** indicates a highly significant difference between the group and the model group (P<0.01); *** indicates a highly significant difference between the group and the model group (P<0.001); △ indicates a significant difference between the group and the four comparative groups (P<0.05).
[0094] 3.2 Effect of the composition on serum triglycerides (TG) in hyperlipidemic rats.
[0095] Table 5. Effects of the composition on serum TG in hyperlipidemic model rats.
[0096]
[0097]
[0098] In the table, ## indicates a highly significant difference between the model group and the blank group (P<0.01); ### indicates a highly significant difference between the model group and the blank group (P<0.001); * indicates a significant difference between the group and the model group (P<0.05); ** indicates a highly significant difference between the group and the model group (P<0.01); △ indicates a significant difference between the group and the four comparative groups (P<0.05).
[0099] 3.3 Effects of the composition on serum low-density lipoprotein cholesterol (LDL-C) in hyperlipidemic model rats.
[0100] Table 6. Effects of the composition on serum LDL-C in hyperlipidemic model rats.
[0101]
[0102] In the table, ### and #### indicate a highly significant difference between the model group and the blank group (P<0.001); ** indicates a highly significant difference between the group and the model group (P<0.01); *** indicates a highly significant difference between the group and the model group (P<0.001); △ indicates a significant difference between the group and the four comparative groups (P<0.05).
[0103] As shown in Tables 4-6, compared with the blank group, the levels of total cholesterol, triglycerides, and low-density lipoprotein cholesterol in the serum of the model group were significantly increased, indicating that the high-fat diet could increase the levels of total cholesterol, triglycerides, and low-density lipoprotein cholesterol in rats, and the hyperlipidemic rat model was successfully established.
[0104] Compared with the model group, the total cholesterol content of Examples 1-4 and Comparative Example 4 was significantly reduced (p<0.05); compared with the model group, the total cholesterol content of Comparative Example 1-3 showed no significant change (p>0.05); compared with Comparative Example 4, the total cholesterol content of Example 4 was significantly reduced (p<0.05). Therefore, the compositions prepared in Examples 1-4 can reduce the total cholesterol content of hyperlipidemic rats, while the compositions prepared in Comparative Examples 1-3 cannot reduce the total cholesterol content of hyperlipidemic rats.
[0105] Compared with the model group, the triglyceride levels in Examples 1-4 and Comparative Example 4 were significantly reduced (p<0.05); compared with the model group, the triglyceride levels in Comparative Examples 1-3 showed no significant change (p>0.05); compared with Comparative Example 4, the triglyceride level in Example 4 was significantly reduced (p<0.05). Therefore, the compositions prepared in Examples 1-4 can all reduce triglyceride levels in hyperlipidemic rats, while the compositions prepared in Comparative Examples 1-3 cannot reduce triglyceride levels in hyperlipidemic rats.
[0106] Compared with the model group, the low-density lipoprotein cholesterol (LDL-C) levels in Examples 1-4 and Comparative Group 4 were significantly reduced (p<0.05); compared with the model group, the LDL-C levels in Comparative Groups 1-3 showed no significant change (p>0.05); compared with Comparative Group 4, the LDL-C level in Example 4 was significantly reduced (p<0.05). Therefore, the compositions prepared in Examples 1-4 can reduce the LDL-C levels in hyperlipidemic rats, while the compositions prepared in Comparative Groups 1-3 cannot reduce the LDL-C levels in hyperlipidemic rats.
[0107] Therefore, it can be seen that the compositions prepared in Examples 1 to 4 can significantly reduce blood lipids in hyperlipidemic rats. In the formulation of this invention, hawthorn, lotus leaf, and Pu-erh tea have a synergistic effect in enhancing and assisting in maintaining healthy blood lipids.
Claims
1. A composition for assisting in maintaining healthy blood lipids, characterized in that, The composition comprises the following ingredients in the following weight proportions: 80-120 parts hawthorn, 55-95 parts lotus leaf, 55-95 parts Pu-erh tea, 40-80 parts salvia miltiorrhiza, 40-80 parts kudzu root, and 20-40 parts Panax notoginseng.
2. The composition according to claim 1, characterized in that, The composition comprises the following ingredients in the following weight proportions: 90-110 parts hawthorn, 70-90 parts lotus leaf, 70-90 parts Pu-erh tea, 50-70 parts salvia miltiorrhiza, 50-70 parts kudzu root, and 30-40 parts Panax notoginseng.
3. The composition according to claim 1, characterized in that, The composition comprises the following ingredients in the following weight proportions: 100-105 parts hawthorn, 80-85 parts lotus leaf, 80-85 parts Pu-erh tea, 60-70 parts salvia miltiorrhiza, 60-70 parts kudzu root, and 35-40 parts Panax notoginseng.
4. The composition according to claim 1, characterized in that, The weight ratio of the lotus leaf to the Pu-erh tea is 1:0.8 to 1.2, preferably 1:0.9 to 1.
1.
5. The composition according to claim 1, characterized in that, The sum of the weight percentages of the lotus leaf and the Pu-erh tea is greater than the sum of the weight percentages of the dan ginseng and the kudzu root.
6. The composition according to claim 5, characterized in that, The ratio of the sum of the weight parts of the lotus leaf and the Pu-erh tea to the sum of the weight parts of the salvia miltiorrhiza and the kudzu root is 1.2 to 1.3:
1.
7. A method for preparing a composition that helps maintain healthy blood lipids, characterized in that, Includes the following steps, S1: Weigh out hawthorn, lotus leaf, Pu-erh tea, salvia miltiorrhiza, kudzu root, and notoginseng according to the weight proportions of each raw material in the composition according to any one of claims 1 to 6; S2: Add 10 to 14 times the amount of water to hawthorn, lotus leaf, Pu-erh tea, salvia miltiorrhiza, kudzu root, and notoginseng, heat under reflux to obtain the extract; S3: The extract is concentrated under reduced pressure to a relative density of 1.05-1.15, and then filtered through a 300-mesh filter cloth to obtain a concentrated extract; S4: After centrifugation of the concentrated extract, the centrifuged liquid is obtained. After drying the centrifuged liquid, it is passed through a 40-mesh sieve to obtain a composition that helps maintain healthy blood lipids.
8. The preparation method according to claim 7, characterized in that, In step S2, the extraction is performed by heating and reflux 2–4 times, with each reflux lasting 1–2 hours; and / or, In step S3, the temperature for vacuum concentration is 40–80°C, and the vacuum degree for vacuum concentration is -0.04–-0.09 MPa; and / or, In step S4, the centrifugation speed is 10000-16000 rpm and the centrifugation time is 2-5 min.
Citation Information
Patent Citations
Traditional Chinese medicine preparation for treating cardiovascular and cerebrovascular diseases
CN101524421A
